Drug intelligence / Profile preview

FACT-182

Development stage: Preclinical
Lead developer: Factor Bioscience
Modality: CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Other Cell Types → Cell Therapies
Administration: Intravenous

Overview

FACT-182 is an engineered macrophage cell therapy being developed by Factor Bioscience for the treatment of solid tumors. As an internal program, it utilizes Factor Bioscience's proprietary cell-engineering technologies to create macrophages capable of infiltrating and modulating the immunosuppressive tumor microenvironment. The therapy is intended to enhance the immune response against solid malignancies, potentially through direct phagocytosis of tumor cells or by reprogramming the local immune landscape to favor anti-tumor activity. It is currently in the preclinical stage of development.

Beyond the preview

Go deeper on FACT-182.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FACT-182.

Explore the full profile